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Abstract
The toxic side effects of doxorubicin (Dox) limit its long-term use as a lung cancer chemotherapeutic. Additionally, drug
delivery to the deep lung is challenging. To address these challenges, isolated rat Sertoli cells (SCs) were preloaded with Dox
conjugated to lipid micelle nanoparticles (SC-DLMNs) and delivered to mouse lungs. These immunocompetent cells, when
injected intravenously, travel to the lung, deliver the payload, and get cleared by the system quickly without causing any
adverse reaction. We observed that SC-DLMNs effectively treated Lewis lung carcinoma 1-induced lung tumors in mice and
the drug efficacy was comparable to SC-Dox treatment. Mice treated with SC-DLMNs also showed significantly less toxicity
compared to those treated with SC-Dox. The encapsulation of Dox in lipid micelle nanoparticles reduced the toxicity of Dox
and the SC-based delivery method ensured drug delivery to the deep lung without evoking any immune response. Taken
together, these results provide a novel SC-based nanoparticle drug delivery method for improved therapeutic outcome of
cardiotoxic antilung cancer drugs.
Keywords
Sertoli cell, lung cancer, lipid micelle nanoparticles, drug toxicity, doxorubicin (Dox)

Introduction
Lung cancer is one of the leading causes of death in the
western world.1 Surgery, radiotherapy, chemotherapy, and
immunotherapy remain the standard treatment options for
lung cancers.2 Despite several improvements in chemotherapeutic drug delivery systems, delivery of drugs to the lungs,
especially to the deep lung, remains a major challenge. One
of the main drug delivery routes to the lung is the transpulmonary route, but it is limited by the lung’s tendency to
expel materials entering through the airways and, therefore,
the inability of the drug to stay in contact with the diseased
tissues for an adequate amount of time.3 Moreover, the
epithelial barrier of the deep lung has a high resistance
(1,200 Ocm 2 higher than intestinal mucosa) 4 and is
equipped with fewer transporter and channel proteins,4,5
which reduces drug absorption to a great extent.
The use of nanoparticle-mediated delivery of therapeutic
molecules may be promising in overcoming the obstacles in
drug delivery to the lungs and enhancing drug release. Attempts
have been made to use lipid, polylactide-co-glycolide, albumin, poly(o-pentadecalactone-co-butylene-co-succinate),
cerium oxide, gold, ultrasmall superparamagnetic iron oxide

nanoparticles, superparamagnetic iron oxide, lipidpolycation-DNA, N-[1-(2,3-dioleoyloxyl)propyl]-NNNtrimethylammoniummethyl sulfate, silica-overcoated
magnetic cores, and polyethyleneglycol phosphatidylethanolamine (PE) nanoparticles to deliver drugs and
therapeutic genes to treat lung cancers.1 Although several
nanoparticle-mediated anticancer therapeutic systems have
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reached clinical trials or received United States Food and
Drug Administration (FDA) approval,6 delivery of these
nanoparticles to the deep lung has met with little success.
Recently, Howell et al. have formulated lipid micelle nanoparticles (LMNs) using FDA approved ingredients such as
polyethylene glycol (PEG-2000), PE, DC-cholesterol, and
dioleoyl-PE (DOPE). The core of these particles can be filled
with drugs such as doxorubicin (Dox) or magnetic resonance
imaging contrast agents and thus serve as an excellent drug
delivery platform for theranostics in biological systems, especially the lungs.7,8,9,10 Dox is a widely used chemotherapeutic
agent to treat lung, breast, bone, and brain cancers. However,
its use is severely restricted because of its toxic side effects
such as esophagitis, cardiac toxicity, and hepatotoxicity. In
this study, we have shown that encapsulating Dox in LMNs
reduces Dox-induced toxicity.
Overcoming the physiological rejection and immune
responses against nanoparticles remains an obstacle for drug
delivery to the lungs. One way to overcome this obstacle is to
develop a biocompatible cell-based drug delivery system
which will be able to deliver the payload to the target organ
and at the same time will help in avoiding physiological and
immune rejection. Owing to their immunocompetent properties, Sertoli cells (SCs) have long been used to facilitate
allo- and xenogeneic cell transplantation.11,12 In addition,
xenogeneic SCs have been found to induce donor-specific
tolerance in the host when administered intravenously.10
Dufour et al. have shown immunoprotection rendered by rat
SCs for islet cells during xenotransplantation without immunosuppression.13,14 Recently, Halley et al. used genetically
engineered SCs producing insulin to treat diabetes in mice.15
Previously, we described a method to deliver curcumin to
the deep lungs of normal mice using isolated rat SCs3 in
asthmatic mice. Since SCs are expected to deliver drugs in
the capillary bed, where a majority of metastatic tumors are
found, we reasoned that SCs packed with nanodrug delivery
systems carrying anticancer drugs may provide an ideal system. In this study, we delivered Dox to treat Lewis lung
carcinoma 1 (LLC1)-induced lung cancer in mice. We also
encapsulated Dox in lipid micellar nanoparticles (DLMN) in
order to reduce its toxicity while keeping its efficacy unaltered. Then we preloaded this formulation in SCs which
enabled us to deliver the drug to the deep lung where drug
delivery is otherwise limited. The results of these studies
demonstrate that SC-loaded DLMNs provide an effective
approach to treat lung cancer with significantly reduced
Dox-induced toxicity.
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start date until the study end date. All animals used in this
study were coded and analysis of the results was performed by
persons blinded to the experimental groups.

Preparation of Nanoparticles
LMNs were prepared by the method described by Howell
et al.9 with some modifications. Briefly, Dox hydrochloride
(Dox; LC Laboratories, Woburn, MA, USA) along with 4M
equivalents of triethylamine was added to chloroform and the
mixture was sonicated for 30 min to dissolve the Dox. Dox was
encapsulated inside micelles. PEG-2000 PE (0.1 mg, 2% of
total), 3b-[N-(Dimethylaminoethane)carbamoyl]cholesterol
(DC cholesterol) (7.9 mM, 3.95 mg, 66% of total), and DOPE
(2.6 mM, 1.95 mg, 32% of total) were added to 1.5 mL of
chloroform. Three milligrams of the Dox in chloroform were
then added to this solution. To ensure complete solubilization, the reaction solution was sonicated in a Branson 2510
sonicator (Thermo - Fisher Scientific, Weehawken, NJ,
USA) for 20 min. The solution was then left to evaporate
for 2 h in a vacuum oven at 40  C. The dry film was heated at
80  C for 2 min. Then, 2 mL of water was added, and the
solution was again sonicated. The DLMNs were then filtered
through a 0.45-mm syringe filter and subsequently dialyzed
(3,000 kDa molecular weight cut off) in water overnight.
Once the nanoparticles were taken off dialysis they were
frozen at 80  C for 2 h. The frozen solution was then freeze
dried at 0.05 mBar overnight and stored as a powder at 4  C
until further use. The dried micelles were dissolved in water
and filled with Dox at a concentration of 0.26 mg Dox per
microgram of LMN to produce DLMN.

Induction of Lung Tumors in Mice
LLC1 cells (cat # CRL-1642, ATCC, Manassus, VA, USA)
were cultured with Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin and streptomycin. A total of 80 C57BL/6
mice were used to induce lung tumors. To induce lung
tumors, 1 million (M) LLC1 cells in sterile phosphate buffered saline (PBS) were injected intravenously (iv) through
the tail vein of the mice. Mice were returned to their housing
and observed throughout the period of experiments. Body
weight was taken for each mouse before LLC1 injection as
well as at the termination of the experiment for the surviving
mice.

SC Culture, Loading, and Injection into Mice
Materials and Methods
All animal experimental protocols used in this study were
approved by the Institutional Animal Care and Use Committee of the University of South Florida, Tampa, FL, USA. Rats
and mice used in the study were housed in the animal facility
with food and water available ad libitum during the period of
the study. Animal health was monitored daily from the study

Seventeen day old Sprague-Dawley (SD) rats were used for
SC isolation. Rat pups were euthanized by carbon dioxide
inhalation and testes were surgically removed, then digested
sequentially with trypsin and collagenase as reported by
Cameron et al. and Gloat.3,16,17 Cells were maintained in
DMEM/F12 supplemented with insulin–transferrin–selenium (1% ITS, Invitrogen, Waltham, MA, USA) and
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gentamicin sulfate (50 mg/mL, Sigma, Saint Louis, MO,
USA) for at least 10 d. Upon 90% confluency, SCs were
incubated with Dox (65 mg/mouse/dose), DLMNs (250 mg/
mouse/dose, 65 mg do equivalent), or LMNs (250 mg/mouse/
dose) for 3 h and then aggressively washed with PBS to
remove molecules attached loosely on the surface of the
cells; they were then resuspended in 100 mL of sterile saline
for iv injection. Ten days after LLC1 injection, mice were
randomly divided into 5 groups. Four million SCs per mouse
were injected through iv route 10 d and 17 d after LLC1
injection. The control group (LLC1 group) did not receive
any SCs. The SC group received SCs only, the SC-Dox group
received SCs loaded with Dox, the SC-LMN group received
SCs loaded with LMN, and the SC-DLMN group received
SCs loaded with DLMN. Naive animals did not receive
any LLC1 injection or any treatment at all (naive group).

Confocal Microscopy
After loading the SCs with Dox, LMN, or DLMN, confocal
fluorescence microscopy was performed on live cells to
capture the Dox fluorescence using Leica TCS SP2 Laser
Scanning Confocal Microscope (Leica Microsystems, Buffalo Grove, IL, USA). Dox fluorescence was quantitated
from the time series images using Image J software (version
1.49, National Institutes of Health [NIH], Bethesda, MD,
USA).

Tissue Collection, Processing, and Histology
Mice were deeply anesthetized 24 d after LLC1 injection
by ketamine and xylazine (100 mg/kg and 20 mg/kg,
respectively). From the pilot experiments, this study period
was determined as optimal with minimal animal suffering.
Therefore, this time period was used for the current study.
Body weight was taken. Blood was collected by cardiac
puncture. This allowed us to maximize blood collection
without distress to the animal. Serum was stored at 80

C until used. The lungs were inflated with 200 mL of sterile
PBS through the trachea, harvested and transferred to 4%
paraformaldehyde (PFA) for fixation. The heart and liver
were also collected and weighed immediately after extraction. The cardiac ventricles were divided into 2 parts. One
part was snap frozen on dry ice and stored at 80  C until
further use. The remaining part was fixed with 4% PFA.
The liver was also snap frozen or fixed with 4% PFA. After
24 h, lungs were dehydrated, infiltrated, and then embedded
in paraffin wax. Five micrometer sections of the whole lung
were collected on glass slides for future staining experiments. The heart and liver were infiltrated with 30%
sucrose solution and embedded in optimum cutting temperature compound. Seven-micrometer thick cryosections
were collected on superfrost plus slides for different staining experiments. Bright field microscopy was performed to
visualize the histological changes in the tissues using
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Olympus 71X microscope (Olympus corporation of the
Americas, Waltham, MA, USA).

Hematoxylin and Eosin (H&E) Staining
H&E staining was performed on lung, heart, and liver sections. Lung sections were stained with H&E using an automated staining system (Leica Autostainer XL). Heart and
liver sections were washed with PBS for 5 min, stained with
H&E for 30 s and 1 min, respectively, and then dehydrated
with graded alcohol, cleared with xylene, and coverslipped
with VectaMount mounting medium (Vector Laboratories
Inc., Burlingame, CA, USA).

Immunohistochemistry
Slide-mounted whole lung sections were immunostained using
rabbit anti-Ki67 antibody (1:100, Spring Biosciences, Pleasanton, CA, USA) with an automated immunostaining system
(Ventana Discovery XT automated system; Ventana Medical
Systems, Tucson, AZ, USA). Slide-mounted heart sections
were washed with PBS, heated in antigen unmasking solution
(1:100; Vector Laboratories Inc., Burlingame, CA, USA) for
20 min at 90  C, incubated in 3% hydrogen peroxide for 20 min,
and washed 3 times in PBS. The sections were then incubated
for 1 h in permeabilization buffer (10% goat serum, 0.1% Triton
X-100 in PBS) at room temperature and incubated overnight at
4  C with rabbit anti-Troponin I antibody (1:200). The following day, sections were washed with PBS and incubated serially
with biotinylated goat anti-rabbit (1:400, Vector Laboratories
Inc.) antibody in antibody solution and avidin-biotin complex
mixture (1:100; Vector Laboratories Inc.) for 1 h at room temperature and visualized using 3,30 -diaminobenzidine (DAB)/
peroxide substrate solution (Vector Laboratories Inc.) with
PBS washes in between. After the final wash, sections were
dehydrated with increasing concentrations of ethanol (70%,
95%, 100%), cleared with xylene, and coverslipped with Vectamount mounting medium.

Measurement of LLC1-Induced Tumor Burden
in the Lung
Low magnification bright field images from H&E-stained
lung sections were collaged and imported to Image J software. Hematoxylin staining intensity was measured from
each lung section and expressed as integrated density.
Ki67 immunoreactivity was also measured from the immunostained sections using Image J.

Enzyme-linked immunosorbent assay (ELISA) for
Cardiac Troponin I (cTnI) Subunit Estimation
cTnI in heart tissue lysates or serum samples was measured
using cTnI ELISA kit (Life Diagnostics, West Chester, PA,
USA) following manufacturer’s instructions. Snap frozen
heart tissues were homogenized using tris-buffered saline
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Fig. 1. Sertoli cells uptake Dox or DLMN in vitro. (A) Live confocal
microscopic images showing the Dox fluorescence (red) in the
Sertoli cells incubated with or without LMN, Dox, or DLMN for
different time periods. Scale bar ¼ 60 m. (B) Image J quantification of
Dox fluorescence shows maximum DLMN uptake by the cells at 3
h post incubation. **P < 0.01 versus Free Dox. ###P < 0.001 versus
LMN. DLMN, Dox conjugated to lipid micelle nanoparticles; LMN,
lipid micelle nanoparticle; Dox, doxorubicin.

(TBS)-ethylenediaminetetraacetic acid (EDTA) buffer with
protease and phosphatase inhibitors (Fisher Scientific). Sample volume was reduced to 25 mL/well for low serum volume
obtained from mice and reagent volumes were adjusted
accordingly. Briefly, 25 mL of samples were incubated in
an antibody coated 96 well plate along with cTnI antibody
conjugated with horse raddish peroxidase (cTnI-HRP) at
room temperature for 1 h, then incubated with 25 mL
3,30 ,5,50 tetramethylbenzidine (TMB, Fisher Scientific) solution for 20 min at room temperature. The reaction was
stopped with 2N H2SO4 and read at 450 nm. A Bradford
assay was performed to estimate the total protein concentrations in the samples used. cTnI concentration was expressed
per milligram of total protein in the respective sample.

Measurement of Liver Enzymes
Aspartate aminotransferase (AST) activity was measured
from the liver lysates using AST colorimetric assay kit from
Biovision (Milpitas, CA, USA) following manufacturer’s
instructions. Fifty milligram of liver samples were homogenized in 200 mL of the assay buffer. After the reaction
mix containing the enzyme mix, developer and substrate
were added to the samples, the plate was incubated at 37  C.
A reading was taken every 30 min for a period of 150 min.
Optical density (OD) value at 450 nm at 30 min was taken
as initial and at 120 min was taken as final. AST activity
was expressed as milliunits per microliter.

Statistical Analyses
All data are presented as mean + standard error of the mean
(SEM). Statistical significance was evaluated by one-way
analysis of variance (ANOVA) with Bonferroni post hoc
test. For the survival analysis, two-way ANOVA with
Tukey’s post hoc test was used for comparison. A P value
of less than 0.05 was considered statistically significant for
all comparisons.

1697

Fig. 2. SC-dox or SC-DLMN increases the survival of LLC1
injected mice and improves the body weight. (A) Kaplan–Meier
survival curve showing the percentage of mice survived (% survival,
mean + SEM) in different groups during 25-d period after LLC1
injection. (B) Histogram shows the percentage change in body
weight (+ SEM) of mice in different experimental groups after
LLC1 injection. *P < 0.05. ***P < 0.001, ns, not significant; SC,
Sertoli cell; Dox, doxorubicin; DLMN, Dox conjugated to lipid
micelle nanoparticles; LLC1, Lewis lung carcinoma 1.

Results
Uptake of Dox by SCs In Vitro
To measure Dox uptake by SCs, upon 90% confluency, SCs
were incubated with Dox or DLMN. Supplementary Figure 1
shows SC culture at day 10. Combined bright field and
fluorescence microscopy showed that following incubation,
Dox, or DLMN entered into SCs within hours without
significantly reducing the number of cells (Supplementary
Fig. 2). The time-series confocal microscopy of live SCs
incubated with LMN, Dox, or DLMN for 1 to 5 h showed
maximum uptake of Dox or DLMN at 3 h (Fig. 1A and B)
postincubation. Image J quantification of live confocal
images showed maximum Dox fluorescence intensity at 3
h postincubation (Fig. 1B). These analyses also indicated
that DLMNs were taken up more efficiently and retained
in the cytoplasm longer than Dox (Fig. 1A). In subsequent
in vivo experiments, we incubated the SCs with Dox,
DLMN, or LMN for 3 h.

Effects of SC-Dox or SC-DLMN Treatments on
the Survival and Body Weight of Mice Induced
with Lung Tumor
To examine the efficacy of drug treatments on survival, a
Kaplan–Meier survival curve (Fig. 2A) was plotted for each
group of mice showing the survival of mice during the period
of the experiments. Only 25% of the LLC1 mice survived
until the end of the experiment. SC-Dox and SC-DLMNtreated animals showed 100% survival while 60% survival
was observed in SC-treated mice. Only 25% of SC-LMNtreated mice survived the period of experiment (Fig. 2A).
Body weight was taken for each mouse at the beginning and
(for the surviving mice) at the end of the experiment. The
naive mice gained about 15% body weight in the entire
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Fig. 3. SC-Dox or SC-DLMN treatment significantly decreased
tumor burden in mice. (A) The upper panel shows H&E staining of
lung sections under different experimental conditions. The lower
panel shows the Ki67 immunostaining of the adjacent lung sections,
counterstained with hematoxylin. (B) Image J analysis of H&E sections shows significant decrease in the hematoxylin staining intensity
after Dox or DLMN treatment. (C) Image J analysis of Ki67 immunoreactivity.**P < 0.01. ***P < 0.001 versus LLC1. SC, Sertoli cell;
Dox, doxorubicin; DLMN, Dox conjugated to lipid micelle nanoparticles; LLC1, Lewis lung carcinoma 1; H&E ¼ hematoxylin and eosin.

period. The untreated mice bearing LLC1 lung tumors, SCtreated groups, and SC-LMN-treated groups surviving the
period of the experiment lost about 10% of their body
weight. On the other hand, the SC-Dox-treated mice gained
weight while SC-DLMN-treated mice showed no change
in body weight during the period of the experiments, thus
showing significant differences from the control groups
(Fig. 2B).

Effect of Drug Treatments on LLC1-Induced Lung
Tumor Formation in Mice
To investigate antitumor efficacy, the effect of drug regimens on LLC1-induced lung tumor formation was examined
in mice. Visual observations of untreated (LLC1), SC, or
SC-LMN mice showed development of tumor nodules covering significant areas of the surface of the lungs. On the
other hand, significantly less nodule formation was observed
in the SC-Dox and SC-DLMN treatment groups. Histological observations of the H&E stained whole lung sections
showed the spread of tumor growth inside the lungs in LLC1
injected mice as well as in the SC and SC-LMN-treated
mice. In comparison to these groups, SC-Dox and SCDLMN-treated groups of mice showed significantly reduced
tumor nodule formation (Fig. 3A, upper panel). Image J
quantitation further confirmed that the tumor nodules were
significantly reduced in SC-Dox and SC-DLMN-treated
groups (Fig. 3B). In addition to these observations, immunostaining with anti-Ki67 antibody of the lung sections
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Fig. 4. DLMN protects the heart from Dox-induced toxicity. Representative bright field images of H&E staining showing tissue
degeneration (*), cellular infiltration (arrow), and vacuolation
(arrow head) of the left ventricular myocardium in SC-Dox or
SC-DLMN-treated mice. (A) Low magnification images, scale bar
¼ 100 m. (B) High magnification images of the boxed areas from (A).
Scale bar ¼ 20 m. (C) cTnI expression in the left ventricular myocardium. Scale bar ¼ 20 m. (D) and (E) Histograms showing elevated
cTnI expression in the serum (D) or in the left ventricular myocardium (E) in SC-Dox-treated mice as determined by ELISA, *P <
0.05. SC, Sertoli cell; Dox, doxorubicin; DLMN, Dox conjugated
to lipid micelle nanoparticles; cTnI, cardiac troponin I; H&E ¼
hematoxylin and eosin.

showed a substantially large number of Ki67-positive proliferating cells in the untreated (LLC1), SC, and SC-LMNtreated mice. Ki67 immunoreactivity was significantly
reduced in mice after treatment with SC-Dox or SCDLMN (Fig. 3A, lower panel, C). These observations indicate that SC-Dox or SC-DLMN treatments reduced the
LLC1-induced tumor burden in mice. It was also observed
that hematoxylin staining or Ki67 staining intensities in SCDLMN group were not significantly different from the
SC-Dox-treated group, thus indicating that the effects of
SC-DLMN treatment were comparable to those of SC-Dox
treatment.

DLMN Treatment Induced Less Cardiac Toxicity
in Mice
Although a potent chemotherapeutic drug, Dox is highly
cardiotoxic. To evaluate the cardiotoxic effect of Dox, we
evaluated the cardiac tissues histologically as well as by
measuring the cTnI levels of heart and serum from SCDox or SC-DLMN-treated mice. Histological observations
of H&E-stained cardiac tissues from SC-Dox-treated mice
showed signs of cardiac toxicity including increased cellular
infiltration in the myocardium with significant myocardial
tissue necrosis and vacuolation (Fig. 4A and B). On the other
hand, the myocardium of SC-DLMN-treated mice showed
significantly reduced cellular infiltration, tissue necrosis,
and vacuolation (Fig. 4A and B). Immunostaining of cardiac
sections with anti-cTnI antibody showed elevated cTnI

Das et al
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AST activity was significantly reduced in the SC-DLMN
group compared to the SC-Dox treatment group (Fig. 5B).
These observations demonstrate that DLMN is less hepatotoxic than Dox.

Discussion

Fig. 5. DLMN protects the liver from Dox-induced toxicity in
mice. (A) Representative images of H&E staining of liver sections
showing the hepatic damage in SC-Dox-treated mice. Left panel
shows low magnification images (scale bar ¼ 100 m) and right panel
shows magnified images of the boxed areas in the low magnification
images (scale bar ¼ 20 m). Vacuolation (arrow head) and hepatocellular degeneration (arrow) are evident in the SC-Dox group. (B)
Histogram showing hepatic AST activity levels in naive, SC-Dox, or
SC-DLMN-treated mice. *P < 0.05 compared to naive compared to
SC-Dox. SC, Sertoli cell; Dox, doxorubicin; DLMN, Dox conjugated to lipid micelle nanoparticles; AST, aspartate aminotransferase; H&E ¼ hematoxylin and eosin.

expression in SC-Dox-treated myocardium. Expression of
cTnI in the myocardium of SC-DLMN-treated mice was
reduced (Fig. 4C). Estimation of cTnI levels in the serum
samples by ELISA showed elevated cTnI level in the SCDox treatment group indicating cardiac toxicity caused by
Dox treatment in that group (Fig. 4D), subsequently confirmed by estimation of cTnI in the cardiac lysate in the same
group. In both serum and cardiac lysates, cTnI levels were
significantly lower in the SC-DLMN group compared to the
SC-Dox treatment group (Fig. 4D, E). This observation
clearly shows that SC-DLMN induced less cardiac toxicity
in comparison to SC-Dox treatment in mice.

DLMN Treatment Induced Less Hepatic Toxicity
in Mice
Dox is also known to cause hepatic toxicity, limiting its use
in the treatment of lung cancer to a great extent. In this study,
to evaluate the hepatic toxicity caused by Dox or DLMN,
histological observations were performed and liver AST
activities were measured in the liver homogenates of
SC-Dox or SC-DLMN-treated mice. Liver sections were
stained with H&E. Figure 5A shows images of the liver
tissue sections from different experimental groups. The
SC-Dox treatment group showed clear hepatocellular degeneration and increased cellular vacuolation and sinusoidal
dilation—all indicative of hepatic toxicity. These indications
were either absent or significantly reduced in the
SC-DLMN-treated group (Fig. 5A). The AST assay showed
increased AST activity in the liver homogenates of the
SC-Dox group, indicating hepatic toxicity caused by Dox.

A major finding of our study is that SCs can serve as a carrier
of drugs and nanoparticulate drugs to the deep lung, which
was probed herein using Dox, an anthracycline that has
served as a powerful and widely used chemotherapeutic
agent for a broad variety of solid and hematologic neoplasms. In order to achieve effective treatment outcomes in
lung cancer pathologies, active compounds need optimal
local delivery and assured distribution with higher penetration into the alveolar region of the lung to maximize their
therapeutic effects. But current methodological limitations
make drug delivery to the deep lung difficult and result in
poor treatment outcome. The “nano-cell” drug delivery
approach described in this report has many advantages:
(1) it avoids immune rejection: cell-mediated immunity, target cell apoptosis, and complement-mediated cell lysis12,18;
(2) it provides immunoprotection of allo- and xenogeneic
cell transplants13; (3) SCs (*30–50 mm) appear to become
entrapped in the precapillary vascular bed of the lung
(*5 mm) and undergo lysis to release the nanoparticulate
drugs, and the lysed cells are cleared3,12 within 15 min from
the system without deleterious effects to the individual.
These properties have made SCs a great cellular carrier of
therapeutic molecules. Although our observations indicate
improved survival of the drug-loaded SC-treated mice in
comparison to tumor bearing mice treated with free drug,
at this point, the reason is not well understood and needs
further investigation.
Another finding our evidence shows is that SCs are efficient in loading and delivering cytotoxic payloads such as
LMN, Dox, or DLMN to the lung. Presumably, the drug was
delivered when the large SCs burst in the capillary bed of the
lung, releasing Dox molecules that then exerted their effects
by inhibiting tumor growth. We do not have any evidence
that SCs had an effect on modifying the therapeutic or safety
potential of Dox or DLMN. The therapeutic efficacy of
DLMN in reducing the tumor burden and increasing the
survival of the mice was found to be comparable to Dox.
Also, the treated mice either maintained or gained body
weight. Thus, this SC-based nanodrug delivery method was
able to deliver an optimal amount of drug to the lung to
produce the therapeutic effects.
Dox is a potent chemotherapeutic agent and different
formulations of Dox are either in clinical trials or available
for therapy.19 But, as described in the literature, the clinical
use of Dox is severely hampered by its adverse side effects
such as shortness of breath, ankle swelling, fatigue/persistent
tiredness, irregular heartbeat, myelosuppression, esophagitis, hepatotoxicity20–22, and acute cardiac toxicity.7,8,23–27
It increases reactive oxygen species (ROS) in several organs
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and damages them, with toxic effects that are cumulative
and mostly irreversible. Inflammatory reactions in the
veins used for injection have also been observed.28 Cardiac toxicity and heart failure are common complications
in patients receiving Dox chemotherapy. 7,8,26,29 In a
recent study conducted by Loncar-Turukalo et al., treatment of adult male Wistar rats for 15 d with 15 mg/kg
intraperitoneal Dox caused cardiotoxicity as confirmed by
histological examination. Although echocardiography
showed no development of heart failure, the increase in
heart rate variability reflected subtle microscopic changes
in cardiac toxicity in these rats.7 cTnI is a useful biomarker
of myocardial injury.25,30–32 Engle et al. described a well
correlated relationship between cardiac myopathy and cTnI
concentration in the serum.30 In line with these observations, we have shown histological changes in the myocardium as well as increased cardiac and serum cTnI
concentrations in SC-Dox-treated mice, indicating Doxinduced cardiomyopathy.
In addition to cardiac toxicity, hepatotoxicity is another
serious side effect that limits the use of Dox. Singla et al.
have observed that administration of Dox at a dose of 25 mg/
kg for 3 d induced hepatotoxicity and oxidative stress in SD
rats. They observed significant decreases in activity of catalase, superoxide dismutase, glutathione-S-transferase, glutathione peroxidase, and glutathione reductase in rat liver
supernatants along with increased activity of serum glutamic
pyruvic transaminase (SGPT) and serum glutamic oxaloacetic
transaminase.20 Dox-induced hepatic arterial and parenchymal necrosis were observed following Dox administration
by Verret et al. in pigs 21 and by Rashid et al. in rats.22 In
these studies, decline in hepatic function was indicated by
downregulation of genes including enzymes of lipid and carbohydrate metabolisms.21 Recently, increased AST and ALT
activities along with histopathological changes in the liver
were reported in Dox-treated rats.33,34 In accordance with
these observations in the present study, we have observed
increased hepatic AST levels in SC-Dox-treated mice associated with significant hepatic tissue damage.
In this study, we have shown that Dox-induced cardiac
toxicity was significantly reduced in the SC-DLMN-treated
mice. Several attempts have been made to reduce Doxinduced toxicity and improve the efficacy of Dox.23,35–41 Since
the first FDA approval of pegylated Dox, or Doxil, in 1990,
several nanotechnological formulations of the drug have
entered clinical trials and shown significant pharmacologic
advantages and added clinical value over Dox. 19,23
Liposomal Dox not only improves drug penetration into
tumors but also decreases drug clearance and thereby
increases the duration of therapeutic drug effects. This
formulation of Dox also modulates toxicity, specifically
cardiotoxicity. In the present study, we conjugated Dox to
LMN particles in an attempt to reduce drug-induced toxicities. In previous studies conducted by our laboratory,
we observed that LMN particles were efficient in delivering drugs or genes to the lungs without any adverse
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effects.9,10 The data from the present study support the
previous observations as DLMN was comparably effective to Dox. Moreover, loading into SCs enabled the
delivery of DLMN to the deepest areas of the lung, thus
indicating the excellent therapeutic potential of this novel
delivery method with significantly reduced cardiac and
hepatic toxicity and increased clinical efficacy.

Conclusion
In conclusion, in this study, we developed a novel method to
deliver chemotherapeutic drugs to treat lung cancer. Conjugating Dox with LMN particles (DLMN) significantly
reduced the toxic side effects of this drug while keeping its
efficacy unaltered. Preloading the formulation in immunocompetent SCs facilitated delivery of the drug to the deep
lung and successful treatment of lung tumors which would
otherwise be difficult to treat.
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